Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Good news for TIL therapy patients heading home. A new study from Memorial Sloan Kettering found that advanced melanoma patients treated with lifileucel had very few severe side effects after leaving the hospital — suggesting that the intensive post-discharge monitoring used for CAR-T therapy may not be necessary for this treatment.
Patients with advanced melanoma who received lifileucel — a tumor-infiltrating lymphocyte (TIL) therapy — appear to fare well after hospital discharge, according to a new retrospective study out of Memorial Sloan Kettering Cancer Center. Researchers analyzed 51 patients treated between 2020 and 2024 and found that serious treatment-related side effects after going home were rare, raising questions about whether the intensive follow-up protocols borrowed from CAR-T therapy are actually necessary.
The findings suggest that lifileucel's post-discharge risk profile is meaningfully different from CAR-T therapies, potentially opening the door to more flexible, patient-friendly monitoring approaches.
By the Numbers:
Why it matters: These findings could meaningfully improve quality of life and expand access to care for a growing population of melanoma patients on TIL therapy — by reducing the burden of frequent clinic visits after an already intensive treatment course.
